Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Eupraxia Pharmaceuticals Inc. (EPRX) had Stock-Based Compensation of $8.76M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-41.11M |
|
-- |
|
-- |
|
$38.43M |
|
$-38.43M |
|
$-0.15M |
|
$-38.59M |
|
$-38.58M |
|
$-38.61M |
|
$-38.61M |
|
$-38.61M |
|
$-38.60M |
|
$-38.43M |
|
$-38.20M |
|
39.96M |
|
39.96M |
|
$-1.03 |
|
$-1.03 |
|
| Balance Sheet Financials | |
$85.10M |
|
$0.83M |
|
$1.05M |
|
$86.15M |
|
$5.63M |
|
$0.08M |
|
$0.08M |
|
$5.70M |
|
$50.71M |
|
$80.45M |
|
$80.45M |
|
51.94M |
|
| Cash Flow Statement Financials | |
$-28.55M |
|
$-0.59M |
|
$76.06M |
|
$33.10M |
|
$80.56M |
|
$47.46M |
|
|
Stock-Based Compensation |
$8.76M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.12 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-76.13% |
|
-47.99% |
|
-44.81% |
|
-47.94% |
|
$1.55 |
|
$-0.73 |
|
$-0.71 |
|